$CVS
CVS HEALTH Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000006480323000033 Filed on August 02, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$89.76B	$88.92B
YoY Change	10.6%	10.27%
Cost Of Revenue	$54.69B	$53.54B
YoY Change	8.58%	8.61%
Gross Profit	$35.08B	$35.39B
YoY Change	13.91%	12.89%
Gross Profit Margin	39.08%	39.79%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$9.876B	$31.66B
YoY Change	-63.46%	245.16%
Operating Profit	$3.690B	$3.730B
YoY Change	-193.87%	-18.36%
Interest Expense	$693.0M	-$686.0M
YoY Change	22.44%	-217.67%
% of Operating Profit	18.78%	-18.39%
Other Income/Expense, Net	$22.00M	$22.00M
YoY Change	-46.34%	-48.84%
Pretax Income	$3.019B	$2.570B
YoY Change	-167.75%	-36.21%
Income Tax	$754.0M	$656.0M
% Of Pretax Income	24.98%	25.53%
Net Earnings	$2.261B	$1.901B
YoY Change	-166.19%	-35.58%
Net Earnings / Revenue	2.52%	2.14%
Basic Earnings Per Share	$1.76	$1.48
Diluted Earnings Per Share	$1.75	$1.48
COMMON SHARES
Basic Shares Outstanding	1.284B shares	1.282B shares
Diluted Shares Outstanding	1.290B shares	1.287B shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.19B	$16.89B
YoY Change	-19.02%	12.63%
Cash & Equivalents	$13.04B	$13.81B
Short-Term Investments	$3.145B	$3.080B
Other Short-Term Assets	$3.074B	$4.032B
YoY Change	24.0%	58.68%
Inventory	$17.95B	$17.29B
Prepaid Expenses
Receivables	$32.93B	$9.949B
Other Receivables	$2.603B	$19.60B
Total Short-Term Assets	$70.14B	$67.76B
YoY Change	2.64%	9.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.02B	$30.70B
YoY Change	3.14%	140.55%
Goodwill	$91.26B	$91.26B
YoY Change	16.87%	16.17%
Intangibles	$29.62B	$30.12B
YoY Change	17.76%	7.05%
Long-Term Investments	$21.67B	$22.11B
YoY Change	5.36%	4.69%
Other Assets	$4.825B	$8.119B
YoY Change	-0.49%	67.33%
Total Long-Term Assets	$181.2B	$182.3B
YoY Change	11.23%	8.43%
TOTAL ASSETS
Total Short-Term Assets	$70.14B	$67.76B
Total Long-Term Assets	$181.2B	$182.3B
Total Assets	$251.3B	$250.1B
YoY Change	8.69%	8.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$48.92B	$45.78B
YoY Change	12.63%	8.92%
Accrued Expenses	$22.57B	$24.38B
YoY Change	16.21%	37.5%
Deferred Revenue	$167.0M	$161.0M
YoY Change	125.68%	101.25%
Short-Term Debt	$0.00	$1.000B
YoY Change
Long-Term Debt Due	$2.132B	$1.402B
YoY Change	56.42%	-65.12%
Total Short-Term Liabilities	$81.55B	$79.21B
YoY Change	12.63%	15.7%
LONG-TERM LIABILITIES
Long-Term Debt	$59.78B	$61.42B
YoY Change	17.57%	20.91%
Other Long-Term Liabilities	$6.237B	$31.86B
YoY Change	-7.86%	1388.6%
Total Long-Term Liabilities	$6.237B	$93.28B
YoY Change	-7.86%	4258.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.55B	$79.21B
Total Long-Term Liabilities	$6.237B	$93.28B
Total Liabilities	$176.8B	$177.3B
YoY Change	10.36%	14.58%
SHAREHOLDERS EQUITY
Retained Earnings	$60.34B	$58.87B
YoY Change	10.58%	0.27%
Common Stock	$18.00M	$18.00M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.34B	$72.73B
YoY Change
Total Liabilities & Shareholders Equity	$251.3B	$250.1B
YoY Change	8.69%	8.59%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$2.261B	$1.901B
YoY Change	-166.19%	-35.58%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$2.716B	$5.908B
YoY Change	-70.23%	8.54%
INVESTING ACTIVITIES
Capital Expenditures	$545.0M	$591.0M
YoY Change	-193.97%	-256.76%
Acquisitions
YoY Change
Other Investing Activities	-$226.0M	-$9.771B
YoY Change	0.44%	457.39%
Cash From Investing Activities	-$771.0M	-$10.36B
YoY Change	-4.22%	386.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.697B	3.626B
YoY Change	-16.19%	-247.34%
NET CHANGE
Cash From Operating Activities	2.716B	5.908B
Cash From Investing Activities	-771.0M	-10.36B
Cash From Financing Activities	-2.697B	3.626B
Net Change In Cash	-752.0M	-828.0M
YoY Change	-114.75%	-197.18%
FREE CASH FLOW
Cash From Operating Activities	$2.716B	$5.908B
Capital Expenditures	$545.0M	$591.0M
Free Cash Flow	$2.171B	$5.317B
YoY Change	-77.63%	-8.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2023Q2	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2023Q2	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201812Member
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201812Member
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1000000000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1402000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2023Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	208000000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	228000000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	79206000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69421000000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16609000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16800000000	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	61419000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	50476000000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4588000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4016000000	usd
CY2023Q2	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3267000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2023Q2	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5659000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5835000000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6321000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6730000000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	177069000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	156506000000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1758000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1300000000	shares
CY2023Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48649000000	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48193000000	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	482000000	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	458000000	shares
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	33933000000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	31858000000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	58868000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	56398000000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-858000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1264000000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	72726000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	71469000000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	276000000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	300000000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73002000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	250071000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	228275000000	usd
	us-gaap	Proceeds From Customers ProceedsFromCustomers	175567000000	usd
	us-gaap	Proceeds From Customers ProceedsFromCustomers	151769000000	usd
	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	101318000000	usd
	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	90887000000	usd
	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	41108000000	usd
	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	33920000000	usd
	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	17686000000	usd
	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	15119000000	usd
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	801000000	usd
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	200000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1131000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1150000000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1779000000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1887000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13346000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9006000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3640000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4360000000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4499000000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5010000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1575000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1459000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16474000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	125000000	usd
	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	2807000000	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	-1943000000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-32000000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-54000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18876000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4123000000	usd
	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	1000000000	usd
	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	0	usd
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1787000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2016000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2000000000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	1574000000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	1462000000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	120000000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	348000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	168000000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	329000000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-121000000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-139000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6352000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5111000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	822000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-228000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14127000000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12463000000	usd
	us-gaap	Profit Loss ProfitLoss	4056000000	usd
	us-gaap	Profit Loss ProfitLoss	5394000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2105000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2131000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	307000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	236000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	225000000	usd
	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	87000000	usd
	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	-246000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	804000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2687000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1800000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-469000000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	913000000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	286000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-118000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2033000000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	4334000000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1286000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2492000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	901000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13346000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9006000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	122000000	usd
CY2023Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	1962000000	usd
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	781000000	usd
CY2023Q1	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-99000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71580000000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	1914000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	17000000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	345000000	usd
CY2023Q2	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	129000000	usd
CY2023Q2	us-gaap	Dividends Common Stock DividendsCommonStock	786000000	usd
CY2023Q2	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	66000000	usd
CY2023Q2	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-5000000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73002000000	usd
CY2023Q1	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q2	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2022Q4	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q2	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2023Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75381000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-763000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	300000000	usd
CY2022Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	1972000000	usd
CY2022Q1	us-gaap	Dividends Common Stock DividendsCommonStock	730000000	usd
CY2022Q1	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	3000000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	3039000000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-540000000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	197000000	usd
CY2022Q2	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	267000000	usd
CY2022Q2	us-gaap	Dividends Common Stock DividendsCommonStock	729000000	usd
CY2022Q2	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	2000000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75736000000	usd
CY2022Q1	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2022Q2	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2021Q4	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2022Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q2	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2021Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	17000000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000000	usd
CY2023Q2	cvs	Number Of Pharmacy Plan Members NumberOfPharmacyPlanMembers	110000000	people
CY2023Q2	cvs	Number Of Patients Served Per Year NumberOfPatientsServedPerYear	1000000	patient
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13807000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12945000000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	87000000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	144000000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	233000000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	216000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14127000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	9949000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8983000000	usd
CY2023Q2	cvs	Vendor And Manufacturer Receivables VendorAndManufacturerReceivables	14911000000	usd
CY2022Q4	cvs	Vendor And Manufacturer Receivables VendorAndManufacturerReceivables	12395000000	usd
CY2023Q2	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2296000000	usd
CY2022Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2676000000	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2607000000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3449000000	usd
CY2023Q2	cvs	Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale	29763000000	usd
CY2022Q4	cvs	Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale	27503000000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	313000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	333000000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1219000000	usd
	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	274000000	usd
	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	279000000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	128000000	usd
	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	103000000	usd
CY2023Q2	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1365000000	usd
CY2022Q2	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1055000000	usd
CY2023Q2	us-gaap	Net Investment Income NetInvestmentIncome	274000000	usd
CY2023Q2	us-gaap	Revenues Revenues	88921000000	usd
CY2022Q2	us-gaap	Net Investment Income NetInvestmentIncome	146000000	usd
CY2022Q2	us-gaap	Revenues Revenues	80636000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	608000000	usd
	us-gaap	Revenues Revenues	174199000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	314000000	usd
	us-gaap	Revenues Revenues	157462000000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	9949000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8983000000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	161000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	87000000	usd
	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	165000000	usd
	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	175000000	usd
	cvs	Contractwith Customer Liability Redemptionand Breakage ContractwithCustomerLiabilityRedemptionandBreakage	180000000	usd
	cvs	Contractwith Customer Liability Redemptionand Breakage ContractwithCustomerLiabilityRedemptionandBreakage	182000000	usd
	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	104000000	usd
	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	0	usd
	cvs	Contract With Customer Liability Other Increase Decrease ContractWithCustomerLiabilityOtherIncreaseDecrease	1000000	usd
	cvs	Contract With Customer Liability Other Increase Decrease ContractWithCustomerLiabilityOtherIncreaseDecrease	0	usd
CY2022Q2	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	17490000000	usd
CY2022Q2	cvs	Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement	9187000000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	75967000000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	4669000000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4129000000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1090000000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	3039000000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	3029000000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.31
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.29
	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	35413000000	usd
	cvs	Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement	18511000000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	149248000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	8214000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7130000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1736000000	usd
	us-gaap	Profit Loss ProfitLoss	5394000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5383000000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.06
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2636000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65633000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24803000000	usd
CY2022Q4	us-gaap	Assets Assets	228275000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	10142000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1089000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69421000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4016000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5835000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6730000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	156506000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	56398000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1264000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	71469000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	228275000000	usd
	us-gaap	Profit Loss ProfitLoss	5394000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2131000000	usd
	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	-246000000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	286000000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1286000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	901000000	usd
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	5000000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6000000000	usd
CY2023Q2	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	496000000	usd
CY2023Q2	us-gaap	Severance Costs1 SeveranceCosts1	344000000	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	152000000	usd
CY2023Q2	us-gaap	Payments For Postemployment Benefits PaymentsForPostemploymentBenefits	0	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	3080000000	usd
CY2023Q2	cvs	Long Term Investments Including Assets Held For Sale LongTermInvestmentsIncludingAssetsHeldForSale	22114000000	usd
CY2023Q2	us-gaap	Investments Investments	25194000000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2778000000	usd
CY2022Q4	cvs	Long Term Investments Including Assets Held For Sale LongTermInvestmentsIncludingAssetsHeldForSale	21113000000	usd
CY2022Q4	us-gaap	Investments Investments	23891000000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22268000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	1000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22267000000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	69000000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1433000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20903000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22067000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22063000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1840000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20280000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	1304000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1288000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	7318000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	6942000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	4408000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4078000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	4268000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	3904000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22267000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20903000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	4792	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	7475000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	229000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	6778	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10183000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1204000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	11570	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	17658000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1433000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	9500	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	14228000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1226000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	2784	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4264000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	614000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12284	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	18492000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1840000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	1091000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	16000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	6128000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	386000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	3315000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	348000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	3113000000	usd
CY2023Q2	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	396000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	17658000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1433000000	usd
CY2023Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	383000000	usd
CY2022Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	253000000	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	832000000	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	505000000	usd
CY2023Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	11000000	usd
CY2022Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	9000000	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	21000000	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	18000000	usd
CY2023Q2	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	372000000	usd
CY2022Q2	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	244000000	usd
	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	811000000	usd
	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	487000000	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-98000000	usd
CY2022Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-98000000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-203000000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-173000000	usd
CY2023Q2	us-gaap	Investment Income Net InvestmentIncomeNet	274000000	usd
CY2022Q2	us-gaap	Investment Income Net InvestmentIncomeNet	146000000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	608000000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	314000000	usd
CY2023Q2	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	37000000	usd
CY2023Q2	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-2000000	usd
	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	61000000	usd
	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-3000000	usd
CY2022Q2	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	30000000	usd
CY2022Q2	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-22000000	usd
	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	48000000	usd
	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	16000000	usd
	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	7000000	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	991000000	usd
CY2022Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1052000000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2332000000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2963000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	2000000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	3000000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	5000000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	17000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	73000000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	72000000	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	184000000	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	107000000	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	13000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	42000000	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	26000000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	29000000	usd
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the six months ended June 30, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,705 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,884 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,703 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,998 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive loss on the unaudited condensed consolidated balance sheets. Refer to Note 1 ‘‘Significant Accounting Policies’’ for further information related to the adoption of the long-duration insurance contracts accounting standard. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the six months ended June 30, 2023 and 2022 in the table above exclude $42 million and $41 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $102 million and $149 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. The incurred health care costs for the six months ended June 30, 2022 also exclude $5 million for a premium deficiency reserve related to the Company’s Medicaid products.</span></div>
CY2023Q2	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	8700000000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	345000000	usd
CY2021Q4	us-gaap	Policyholder Funds PolicyholderFunds	522000000	usd
	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	1000000	usd
	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	8000000	usd
	us-gaap	Policyholder Account Balance Policy Charge PolicyholderAccountBalancePolicyCharge	1000000	usd
	us-gaap	Policyholder Account Balance Policy Charge PolicyholderAccountBalancePolicyCharge	1000000	usd
	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	20000000	usd
	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	19000000	usd
	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	5000000	usd
	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	16000000	usd
	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	-126000000	usd
	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-14000000	usd
	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-14000000	usd
CY2023Q2	us-gaap	Policyholder Funds PolicyholderFunds	330000000	usd
CY2022Q2	us-gaap	Policyholder Funds PolicyholderFunds	377000000	usd
CY2023Q2	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0455
CY2022Q2	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0485
CY2023Q2	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2022Q2	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2023Q2	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	323000000	usd
CY2022Q2	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	339000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2021Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	5087000000	usd
	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	457000000	usd
	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	426000000	usd
	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	6000000	usd
	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	4000000	usd
	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	495000000	usd
	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	464000000	usd
	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	88000000	usd
	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	-910000000	usd
	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	2000000	usd
	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	8000000	usd
	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	-7000000	usd
	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	-3000000	usd
CY2023Q2	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3267000000	usd
CY2022Q2	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4140000000	usd
CY2023Q2	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2152000000	usd
CY2022Q2	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2827000000	usd
CY2023Q2	us-gaap	Commercial Paper CommercialPaper	1000000000	usd
CY2022Q4	us-gaap	Commercial Paper CommercialPaper	0	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	1499000000	usd
CY2023Q2	cvs	Short Term Debt Long Term Debt Gross And Lease Obligation ShortTermDebtLongTermDebtGrossAndLeaseObligation	64405000000	usd
CY2022Q4	cvs	Short Term Debt Long Term Debt Gross And Lease Obligation ShortTermDebtLongTermDebtGrossAndLeaseObligation	52753000000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	194000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	200000000	usd
CY2023Q2	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	775000000	usd
CY2022Q4	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	696000000	usd
CY2023Q2	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	63824000000	usd
CY2022Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	52257000000	usd
CY2023Q2	us-gaap	Commercial Paper CommercialPaper	1000000000	usd
CY2022Q4	us-gaap	Commercial Paper CommercialPaper	0	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1402000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2023Q2	cvs	Long Term Debt And Lease Obligation Including Liabilities Held For Sale LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale	61422000000	usd
CY2022Q4	cvs	Long Term Debt And Lease Obligation Including Liabilities Held For Sale LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale	50479000000	usd
CY2023Q2	us-gaap	Commercial Paper CommercialPaper	1000000000	usd
CY2023Q2	us-gaap	Short Term Debt Weighted Average Interest Rate ShortTermDebtWeightedAverageInterestRate	0.0556
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4900000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6000000000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.605
CY2022Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.55
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.21
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.10
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	17000000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-540000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	406000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1303000000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1901000000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3029000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4037000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5383000000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1283000000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1313000000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1283000000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1312000000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1287000000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1321000000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1289000000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1325000000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.48
CY2022Q2	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	0	usd
	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	36000000	usd
	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	0	usd
CY2023Q2	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.10
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.48
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.06
CY2023Q2	cvs	Guarantor Obligations Number Of Leases GuarantorObligationsNumberOfLeases	64	lease
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2022Q2	us-gaap	Revenues Revenues	80636000000	usd
CY2022Q2	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	5002000000	usd
	us-gaap	Revenues Revenues	157462000000	usd
	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	9609000000	usd
CY2023Q2	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	88647000000	usd
CY2023Q2	us-gaap	Net Investment Income NetInvestmentIncome	274000000	usd
CY2023Q2	us-gaap	Revenues Revenues	88921000000	usd
CY2023Q2	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4481000000	usd
CY2022Q2	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	80490000000	usd
CY2022Q2	us-gaap	Net Investment Income NetInvestmentIncome	146000000	usd
CY2022Q2	us-gaap	Revenues Revenues	80636000000	usd
CY2022Q2	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	5002000000	usd
	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	173591000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	608000000	usd
	us-gaap	Revenues Revenues	174199000000	usd
	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	8851000000	usd
	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	157148000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	314000000	usd
	us-gaap	Revenues Revenues	157462000000	usd
	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	9609000000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3234000000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	4669000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	6680000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	8214000000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485000000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	460000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	887000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	922000000	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-98000000	usd
CY2022Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-98000000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-203000000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-173000000	usd
CY2023Q2	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	157000000	usd
CY2022Q2	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	200000000	usd
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
CY2023Q2	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	496000000	usd
CY2022Q2	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	496000000	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
CY2023Q2	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	11000000	usd
CY2022Q2	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	225000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	225000000	usd
CY2023Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-484000000	usd
CY2023Q2	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4481000000	usd
CY2022Q2	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	5002000000	usd
	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	8851000000	usd
	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	9609000000	usd
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000064803-23-000033-index-headers.html	Edgar Link	pending
0000064803-23-000033-index.html	Edgar Link	pending
0000064803-23-000033.txt	Edgar Link	pending
0000064803-23-000033-xbrl.zip	Edgar Link	pending
a06302023ex101.htm	Edgar Link	pending
a06302023ex102.htm	Edgar Link	pending
a06302023ex151.htm	Edgar Link	pending
a06302023ex311.htm	Edgar Link	pending
a06302023ex312.htm	Edgar Link	pending
a06302023ex321.htm	Edgar Link	pending
a06302023ex322.htm	Edgar Link	pending
cvs-20230630.htm	Edgar Link	pending
cvs-20230630.xsd	Edgar Link	pending
cvs-20230630_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
cvs-20230630_cal.xml	Edgar Link	unprocessable
cvs-20230630_def.xml	Edgar Link	unprocessable
cvs-20230630_lab.xml	Edgar Link	unprocessable
cvs-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvs-20230630_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS HEALTH Corp Stock $cvs

2023 Q3 Form 10-Q Financial Statement

#000006480323000033 Filed on August 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS HEALTH Corp Stock $cvs

2023 Q3 Form 10-Q Financial Statement

#000006480323000033 Filed on August 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS HEALTH Corp Stock $cvs